Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study.

Dermatol Ther (Heidelb) · 2026 · PMC13280268 · PMID 42201600

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

Long-term guselkumab use showed a trend toward reduced relapse risk (HR 0.55, 95% CI 0.28–1.06, p = 0.07), whereas no significant difference was observed for secukinumab.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.